Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160663 | 0.87 | ITGB1 (0.33) | PTGDR2ACKR3GPBAR1 | |
| SCHEMBL5175985 | 0.78 | ITGB1 (0.37) | PTGDR2 | |
| SCHEMBL5160833 | 0.78 | ITGB1 (0.50) | ACKR3 | |
| SCHEMBL5163393 | 0.76 | ITGB1 (0.43) | PTGDR2ACKR3 | |
| SCHEMBL5178697 | 0.75 | PTGDR2 (0.34) | PTGDR2DHODH | |
| SCHEMBL5160791 | 0.74 | ITGA4 (0.40) | PTGDR2ACKR3GPBAR1 | |
| SCHEMBL5160938 | 0.70 | ITGB1 (0.43) | — | |
| SCHEMBL5414719 | 0.69 | ITGA4 (0.40) | ACKR3GPBAR1 | |
| SCHEMBL5162846 | 0.69 | ITGA4 (0.37) | ACKR3GPBAR1 | |
| SCHEMBL5160982 | 0.69 | ITGA4 (0.39) | ACKR3GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | PTGDR2 2692/4885ACKR3 707/4885GPBAR1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.